Baseline characteristics for patients with extra-articular rheumatoid arthritis versus controls without extra-articular rheumatoid arthritis
| ExRA | Non-ExRA | p Value | |
|---|---|---|---|
| CRP, C reactive protein; DMARDs, disease-modifying antirheumatic drugs; ExRA, extra-articular rheumatoid arthritis; HAQ, Health Assessment Questionnaire; IQR, interquartile range; TNF, tumour necrosis factor. | |||
| *Data available for 29 patients and 70 controls. | |||
| †Data available for 32 patients and 68 controls. | |||
| ‡Infliximab, etanercept or adalimumab. | |||
| n | 35 | 70 | |
| Sex | |||
| Male | 15 | 30 | |
| Female | 20 | 40 | |
| Age (years; mean (SD)) | 65.5 (11.9) | 65.5 (11.6) | |
| Duration (years; median (IQR)) | 9.6 (2.3–19.4) | 8.6 (3.4–18.2) | |
| Swollen joints (mean (SD)) | 6.5 (5.7) | 3.0 (3.4) | 0.002 |
| Ritchie index (mean (SD)) | 9.5 (7.7) | 8.2 (7.6) | 0.41 |
| HAQ* (mean (SD)) | 1.19 (0.88) | 0.75 (0.74) | 0.01 |
| CRP† (mg/l; median (IQR) | 39.5 (11.5–54.5) | <9 (<9–15) | <0.001 |
| DMARDs, n (%) | 18 (51) | 57 (81) | 0.001 |
| Methotrexate, n (%) | 8 (23) | 27 (39) | 0.11 |
| TNF –inhibitors,‡ n (%) | 1 (3) | 7 (10) | 0.19 |
| Glucocorticosteroids, n (%) | 13 (37) | 19 (27) | 0.29 |